The relationship of childhood obesity with cardiomyopathy and heart failure

Pediatric Metabolic Syndrome: Comprehensive Clinical Review and Related Health Issues

Volumn , Issue , 2012, Pages 199-215

  Qureshi, Muhammad Yasir ^a   Wilkinson, James D ^a   Lipshultz, Steven E ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Adolescents; Cardiomyopathy; Heart failure; Obesity; Pediatric

Indexed keywords

EID: 84862834371     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4471-2366-8_10     Document Type: Chapter

References (138)

1. Wong C, Marwick TH. Obesity cardiomyopathy: pathogenesis and pathophysiology. Nat Clin Pract Cardiovasc Med. 2007;4(8):436-43.
2. Alexander JK. The cardiomyopathy of obesity. Prog Cardiovasc Dis. 1985;27(5):325-34.
3. Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2006;113(6):898-918.
4. The NS, Suchindran C, North KE, Popkin BM, Gordon-Larsen P. Association of adolescent obesity with risk of severe obesity in adulthood. JAMA. 2010;304(18):2042-7.
5. Alpert MA, Lambert CR, Panayiotou H, et al. Relation of duration of morbid obesity to left ventricular mass, systolic function, and diastolic filling, and effect of weight loss. Am J Cardiol. 1995;76(16): 1194-7.
6. Nakajima T, Fujioka S, Tokunaga K, Hirobe K, Matsuzawa Y, Tarui S. Noninvasive study of left ventricular performance in obese patients: influence of duration of obesity. Circulation. 1985;71 (3):481-6.
7. Messiah SE, Arheart KL, Luke B, Lipshultz SE, Miller TL. Relationship between body mass index and metabolic syndrome risk factors among US 8- to 14-year-olds, 1999 to 2002. J Pediatr. 2008;153(2):215-21.
8. He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med. 2001;161(7):996-1002.
9. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983;67(5):968-77.
10. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med. 2002;347(5):305-13.
11. Kasper EK, Hruban RH, Baughman KL. Cardiomyopathy of obesity: a clinicopathologic evaluation of 43 obese patients with heart failure. Am J Cardiol. 1992;70(9):921-4.
12. Factor SM, Minase T, Sonnenblick EH. Clinical and morphological features of human hypertensive-diabetic cardiomyopathy. Am Heart J. 1980;99(4):446-58.
13. Whalley GA, Gusso S, Hofman P, et al. Structural and functional cardiac abnormalities in adolescent girls with poorly controlled type 2 diabetes. Diabetes Care. 2009;32(5):883-8.
14. Duflou J, Virmani R, Rabin I, Burke A, Farb A, Smialek J. Sudden death as a result of heart disease in morbid obesity. Am Heart J. 1995;130(2):306-13.
15. Alpert MA, Terry BE, Mulekar M, et al. Cardiac morphology and left ventricular function in normotensive morbidly obese patients with and without congestive heart failure, and effect of weight loss. Am J Cardiol. 1997;80(6):736-40.
16. Malavazos AE, Ermetici F, Coman C, Corsi MM, Morricone L, Ambrosi B. Influence of epi-cardial adipose tissue and adipocytokine levels on cardiac abnormalities in visceral obesity. Int J Cardiol. 2007;121(1):132-4.
17. Daniels SR, Witt SA, Glascock B, Khoury PR, Kimball TR. Left atrial size in children with hypertension: the influence of obesity, blood pressure, and left ventricular mass. J Pediatr. 2002; 141 (2): 186-90.
18. Pritchett AM, Mahoney DW, Jacobsen SJ, Rodeheffer RJ, Karon BL, Redfield MM. Diastolic dysfunction and left atrial volume: a population-based study. J Am Coll Cardiol. 2005;45(1): 87-92.
19. Amad KH, Brennan JC, Alexander JK. The cardiac pathology of chronic exogenous obesity. Circulation. 1965;32(5):740-5.
20. Lauer MS, Anderson KM, Levy D. Separate and joint influences of obesity and mild hypertension on left ventricular mass and geometry: the Framingham Heart Study. J Am Coll Cardiol. 1992; 19(1): 130-4.
21. Karason K, Wallentin I, Larsson B, Sjostrom L. Effects of obesity and weight loss on cardiac function and valvular performance. Obes Res. 1998;6(6):422-9.
22. Messerli FH, Sundgaard-Riise K, Reisin ED, et al. Dimorphic cardiac adaptation to obesity and arterial hypertension. Ann Intern Med. 1983;99(6):757-61.
23. Wikstrand J, Pettersson P, Bjorntorp P. Body fat distribution and left ventricular morphology and function in obese females. J Hypertens. 1993;11(11):1259-66.
24. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322(22):1561-6.
25. Brown DW, Giles WH, Croft JB. Left ventricular hypertrophy as a predictor of coronary heart disease mortality and the effect of hypertension. Am Heart J. 2000;140(6):848-56.
26. Chinali M, de Simone G, Roman MJ, et al. Impact of obesity on cardiac geometry and function in a population of adolescents: the Strong Heart Study. J Am Coll Cardiol. 2006;47(11): 2267-73.
27. Crowley DI, Khoury PR, Urbina EM, Ippisch HM, Kimball TR. Cardiovascular impact of the pediatric obesity epidemic: higher left ventricular mass is related to higher body mass index. J Pediatr. 2011;158(5):709-14.
28. Urbina EM, Gidding SS, Bao W, Pickoff AS, Berdusis K, Berenson GS. Effect of body size, ponderosity, and blood pressure on left ventricular growth in children and young adults in the Bogalusa Heart Study. Circulation. 1995;91(9):2400-6.
29. Yoshinaga M, Yuasa Y, Hatano H, et al. Effect of total adipose weight and systemic hypertension on left ventricular mass in children. Am J Cardiol. 1995;76(11):785-7.
30. Berry C, Sattar N. Stressed hearts in children with obesity and diabetes: a cause for concern?Diabetologia. 2011;54(4):715-8.
31. Kono Y, Yoshinaga M, Oku S, Nomura Y, Nakamura M, Aihoshi S. Effect of obesity on echocardiographic parameters in children. Int J Cardiol. 1994;46(1):7-13.
32. Alpert MA, Lambert CR, Terry BE, et al. Interrelationship of left ventricular mass, systolic function and diastolic filling in normotensive morbidly obese patients. Int J Obes Relat Metab Disord. 1995;19(8):550-7.
33. Rasooly Y, Sasson Z, Gupta R. Relation between body fat distribution and left ventricular mass in men without structural heart disease or systemic hypertension. Am J Cardiol. 1993;71(16): 1477-9.
34. de la Maza MP, Estevez A, Bunout D, Klenner C, Oyonarte M, Hirsch S. Ventricular mass in hypertensive and normotensive obese subjects. Int J Obes Relat Metab Disord. 1994;18(4): 193-7.
35. Li X, Li S, Ulusoy E, Chen W, Srinivasan SR, Berenson GS. Childhood adiposity as a predictor of cardiac mass in adulthood: the Bogalusa Heart Study. Circulation. 2004;110(22): 3488-92.
36. Shah AS, Khoury PR, Dolan LM, et al. The effects of obesity and type 2 diabetes mellitus on cardiac structure and function in adolescents and young adults. Diabetologia. 2011;54(4): 722-30.
37. Ippisch HM, Inge TH, Daniels SR, et al. Reversibility of cardiac abnormalities in morbidly obese adolescents. J Am Coll Cardiol. 2008;51(14):1342-8.
38. Sons HU, Hoffmann V. Epicardial fat cell size, fat distribution and fat infiltration of the right and left ventricle of the heart. Anat Anz. 1986;161(5):355-73.
39. Smith HL, Willius FA. Adiposity of the heart: a clinical and pathologic study of one hundred and thirty-six obese patients. Arch Intern Med. 1933;52:911-31.
40. Carpenter HM. Myocardial fat infiltration. Am Heart J. 1962;63:491-6.
41. Bharati S, Lev M. Cardiac conduction system involvement in sudden death of obese young people. Am Heart J. 1995;129(2):273-81.
42. Alexander JK. Obesity and cardiac performance. Am J Cardiol. 1964;14:860-5.
43. Backman L, Freyschuss U, Hallberg D, Melcher A. Cardiovascular function in extreme obesity. Acta Med Scand. 1973;193(5):437-46.
44. Kaltman AJ, Goldring RM. Role of circulatory congestion in the cardiorespiratory failure of obesity. Am J Med. 1976;60(5):645-53.
45. Sharpe J. Impact of obesity on diastolic function in subjects < or = 16 years of age. Am J Cardiol. 2006;98(5):691-3.
46. Wong CY, O’Moore-Sullivan T, Leano R, Byrne N, Beller E, Marwick TH. Alterations of left ventricular myocardial characteristics associated with obesity. Circulation. 2004;110(19): 3081-7.
47. Beljic T, Miric M. Improved metabolic control does not reverse left ventricular filling abnormalities in newly diagnosed non-insulin-dependent diabetes patients. Acta Diabetol. 1994;31(3):147-50.
48. Poirier P, Bogaty P, Garneau C, Marois L, Dumesnil JG. Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy. Diabetes Care. 2001;24(1):5-10.
49. Vanninen E, Mustonen J, Vainio P, Lansimies E, Uusitupa M. Left ventricular function and dimensions in newly diagnosed non-insulin-dependent diabetes mellitus. Am J Cardiol. 1992;70(3):371-8.
50. Tarumi N, Iwasaka T, Takahashi N, et al. Left ventricular diastolic filling properties in diabetic patients during isometric exercise. Cardiology. 1993;83 (5-6):316-23.
51. Pascual M, Pascual DA, Soria F, et al. Effects of isolated obesity on systolic and diastolic left ventricular function. Heart. 2003;89(10):1152-6.
52. Alpert MA, Terry BE, Lambert CR, et al. Factors influencing left ventricular systolic function in nonhypertensive morbidly obese patients, and effect of weight loss induced by gastroplasty. Am J Cardiol. 1993;71(8):733-7.
53. Koehler B, Malecka-Tendera E, Drzewiecka B, et al. Evaluation of the cardiovascular system in children with simple obesity. Part II. Echocardiographic assessment. Mater Med Pol. 1989;21(2): 131-3.
54. Kimball TR, Daniels SR, Khoury PR, Magnotti RA, Turner AM, Dolan LM. Cardiovascular status in young patients with insulin-dependent diabetes mellitus. Circulation. 1994;90(1): 357-61.
55. Uusitupa M, Siitonen O, Pyorala K, Lansimies E. Left ventricular function in newly diagnosed non-insulin-dependent (type 2) diabetics evaluated by systolic time intervals and echocardiography. Acta Med Scand. 1985;217(4):379-88.
56. Palmieri V, Bella JN, Arnett DK, et al. Effect of type 2 diabetes mellitus on left ventricular geometry and systolic function in hypertensive subjects: Hypertension Genetic Epidemiology Network (HyperGEN) study. Circulation. 2001;103(1):102-7.
57. Mustonen JN, Uusitupa MI, Tahvanainen K, et al. Impaired left ventricular systolic function during exercise in middle-aged insulin-dependent and noninsulin-dependent diabetic subjects without clinically evident cardiovascular disease. Am J Cardiol. 1988;62(17):1273-9.
58. Wong CY, O’Moore-Sullivan T, Leano R, Hukins C, Jenkins C, Marwick TH. Association of subclinical right ventricular dysfunction with obesity. J Am Coll Cardiol. 2006;47(3):611-6.
59. Aasum E, Hafstad AD, Severson DL, Larsen TS. Age-dependent changes in metabolism, contractile function, and ischemic sensitivity in hearts from db/db mice. Diabetes. 2003;52(2):434-41.
60. Mazumder PK, O'Neill BT, Roberts MW, et al. Impaired cardiac efficiency and increased fatty acid oxidation in insulin-resistant ob/ob mouse hearts. Diabetes. 2004;53(9):2366-74.
61. Buchanan J, Mazumder PK, Hu P, et al. Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology. 2005;146(12):5341-9.
62. Peterson LR, Herrero P, Schechtman KB, et al. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation. 2004;109(18): 2191-6.
63. Murray AJ, Anderson RE, Watson GC, Radda GK, Clarke K. Uncoupling proteins in human heart. Lancet. 2004;364(9447):1786-8.
64. Zhou YT, Grayburn P, Karim A, et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci USA. 2000;97(4):1784-9.
65. Szczepaniak LS, Dobbins RL, Metzger GJ, et al. Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging. Magn Reson Med. 2003;49(3):417-23.
66. McGavock JM, Victor RG, Unger RH, Szczepaniak LS. American College of Physicians and the American Physiological Society. Adiposity of the heart, revisited. Ann Intern Med. 2006; 144(7):517-24.
67. Listenberger LL, Schaffer JE. Mechanisms of lipoapoptosis: implications for human heart disease. Trends Cardiovasc Med. 2002;12(3):134-8.
68. Unger R. Lipotoxic diseases. Annu Rev Med. 2002;53:319-36.
69. Minhas KM, Khan SA, Raju SV, et al. Leptin repletion restores depressed {beta-adrenergic contractility in ob/ob mice independently of cardiac hypertrophy. J Physiol. 2005;565 (Pt 2):463-74.
70. Iozzo P, Chareonthaitawee P, Rimoldi O, Betteridge DJ, Camici PG, Ferrannini E. Mismatch between insulin-mediated glucose uptake and blood flow in the heart of patients with Type II diabetes. Diabetologia. 2002;45(10):1404-9.
71. Scheuermann-Freestone M, Madsen PL, Manners D, et al. Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes. Circulation. 2003;107(24):3040-6.
72. Shibata R, Ouchi N, Ito M, et al. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med. 2004;10(12):1384-9.
73. Valle M, Martos R, Gascon F, Canete R, Zafra MA, Morales R. Low-grade systemic inflammation, hypoadiponectinemia and a high concentration of leptin are present in very young obese children, and correlate with metabolic syndrome. Diabetes Metab. 2005;31(1):55-62.
74. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adi-ponectin, in obesity. Biochem Biophys Res Commun. 1999;257(1):79-83.
75. Arnaiz P, Acevedo M, Barja S, et al. Adiponectin levels, cardiometabolic risk factors and markers of subclinical atherosclerosis in children. Int J Cardiol. 2010;138(2):138-44.
76. Winer JC, Zern TL, Taksali SE, et al. Adiponectin in childhood and adolescent obesity and its association with inflammatory markers and components of the metabolic syndrome. J Clin Endocrinol Metab. 2006;91(11):4415-23.
77. Pilz S, Horejsi R, Moller R, et al. Early atherosclerosis in obese juveniles is associated with low serum levels of adiponectin. J Clin Endocrinol Metab. 2005;90(8):4792-6.
78. Chu NF, Shen MH, Wu DM, Lai CJ. Relationship between plasma adiponectin levels and metabolic risk profiles in Taiwanese children. Obes Res. 2005;13(11):2014-20.
79. Beauloye V, Zech F, Tran HT, Clapuyt P, Maes M, Brichard SM. Determinants of early atherosclerosis in obese children and adolescents. J Clin Endocrinol Metab. 2007;92(8):3025-32.
80. Pervanidou P. Associations between circulating N-terminal pro-Brain Natriuretic Peptide (NT-proBNP) and adiponectin concentrations depend on obesity level in female adolescents: gender dimorphic findings. Horm Metab Res. 2009;41(11):829-33.
81. Rasouli N, Kern PA. Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab. 2008;93 (11 Suppl 1):S64-73.
82. Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112(12):1821-30.
83. Alpert MA. Obesity cardiomyopathy: pathophysiology and evolution of the clinical syndrome. Am J Med Sci. 2001;321(4):225-36.
84. Alexander JK, Dennis EW, Smith WG, Amad KH, Duncan WC, Austin RC. Blood volume, cardiac output, and distribution of systemic blood flow in extreme obesity. Cardiovasc Res Cent Bull. 1962;1:39-44.
85. Messerli FH, Christie B, DeCarvalho JG, et al. Obesity and essential hypertension. Hemodynamics, intravascular volume, sodium excretion, and plasma renin activity. Arch Intern Med. 1981;141(1):81-5.
86. de Divitiis O, Fazio S, Petitto M, Maddalena G, Contaldo F, Mancini M. Obesity and cardiac function. Circulation. 1981;64(3):477-82.
87. Agarwal N, Shibutani K, SanFilippo JA, Del Guercio LR. Hemodynamic and respiratory changes in surgery of the morbidly obese. Surgery. 1982;92(2):226-34.
88. Giacchetti G, Faloia E, Mariniello B, et al. Overexpression of the renin-angiotensin system in human visceral adipose tissue in normal and overweight subjects. Am J Hypertens. 2002;15(5): 381-8.
89. Goodfriend TL, Kelley DE, Goodpaster BH, Winters SJ. Visceral obesity and insulin resistance are associated with plasma aldosterone levels in women. Obes Res. 1999;7(4):355-62.
90. Harte A, McTernan P, Chetty R, et al. Insulin-mediated upregulation of the renin angiotensin system in human subcutaneous adipocytes is reduced by rosiglitazone. Circulation. 2005; 111(15): 1954-61.
91. Brilla CG, Matsubara LS, Weber KT. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol. 1993;25(5): 563-75.
92. Corry DB, Tuck ML. Obesity, hypertension, and sympathetic nervous system activity. Curr Hypertens Rep. 1999;1(2):119-26.
93. Festa A, D'Agostino Jr R, Hales CN, Mykkanen L, Haffner SM. Heart rate in relation to insulin sensitivity and insulin secretion in nondiabetic subjects. Diabetes Care. 2000;23(5):624-8.
94. Sivitz WI, Wayson SM, Bayless ML, Sinkey CA, Haynes WG. Obesity impairs vascular relaxation in human subjects: hyperglycemia exaggerates adrenergic vasoconstriction arterial dysfunction in obesity and diabetes. J Diabetes Complications. 2007;21(3):149-57.
95. Sundell J, Laine H, Luotolahti M, et al. Obesity affects myocardial vasoreactivity and coronary flow response to insulin. Obes Res. 2002;10(7):617-24.
96. Wang T. Obesity and the Risk of New-Onset Atrial Fibrillation. JAMA. 2004;292(20): 2471-7.
97. Dublin S, French B, Glazer NL, et al. Risk of new-onset atrial fibrillation in relation to body mass index. Arch Intern Med. 2006;166(21):2322-8.
98. Zacharias A, Schwann TA, Riordan CJ, Durham SJ, Shah AS, Habib RH. Obesity and risk of new-onset atrial fibrillation after cardiac surgery. Circulation. 2005;112(21):3247-55.
99. Drenick EJ, Fisler JS. Sudden cardiac arrest in morbidly obese surgical patients unexplained after autopsy. Am J Surg. 1988;155(6):720-6.
100. Messerli FH, Nunez BD, Ventura HO, Snyder DW. Overweight and sudden death. Increased ventricular ectopy in cardiomyopathy of obesity. Arch Intern Med. 1987;147(10):1725-8.
101. Alpert MA, Terry BE, Cohen MV, Fan TM, Painter JA, Massey CV. The electrocardiogram in morbid obesity. Am J Cardiol. 2000;85(7):908-10.
102. Eisenstein I, Edelstein J, Sarma R, Sanmarco M, Selvester RH. The electrocardiogram in obesity. J Electrocardiol. 1982;15(2):115-8.
103. Okin PM, Roman MJ, Devereux RB, Kligfield P. ECG identification ofleft ventricular hypertrophy Relationship of test performance to body habitus. J Electrocardiol. 1996;29 (Suppl): 256-61.
104. Alpert MA. Value and limitations of echocardiography in the assessment of obese patients. Echocardiography. 1986;3(3):261-72.
105. Stoddard MF, Tseuda K, Thomas M, Dillon S, Kupersmith J. The influence of obesity on left ventricular filling and systolic function. Am Heart J. 1992;124(3):694-9.
106. Leong DP, De Pasquale CG, Selvanayagam JB. Heart failure with normal ejection fraction: the complementary roles of echocardiography and CMR imaging. JACC Cardiovasc Imaging. 2010;3(4):409-20.
107. Hoit BD. Strain and strain rate echocardiography and coronary artery disease. Circ Cardiovasc Imaging. 2011;4(2):179-90.
108. Ferraro S, Perrone-Filardi P, Desiderio A, et al. Left ventricular systolic and diastolic function in severe obesity: a radionuclide study. Cardiology. 1996;87(4):347-53.
109. Abidov A, Hachamovitch R, Berman DS. Modern nuclear cardiac imaging in diagnosis and clinical management of patients with left ventricular dysfunction. Minerva Cardioangiol. 2004;52(6):505-19.
110. Orakzai SH, Orakzai RH, Nasir K, Budoff MJ. Assessment of cardiac function using multidetector row computed tomography. J Comput Assist Tomogr. 2006;30(4):555-63.
111. Epstein FH. MRI of left ventricular function. J Nucl Cardiol. 2007;14(5):729-44.
112. Iacobellis GG. Cardiac adiposity and cardiovascular risk: potential role of epicardial adipose tissue. Curr Cardiol Rev. 2007;3(1):11-4.
113. Lainscak M, von Haehling S, Anker SD. Natriuretic peptides and other biomarkers in chronic heart failure: from BNP, NT-proBNP, and MR-proANP to routine biochemical markers. Int J Cardiol. 2009;132(3):303-11.
114. Iwanaga Y, Kihara Y, Niizuma S, et al. BNP in overweight and obese patients with heart failure: an analysis based on the BNP-LV diastolic wall stress relationship. J Card Fail. 2007;13(8):663-7.
115. Taylor JA, Christenson RH, Rao K, Jorge M, Gottlieb SS. B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide are depressed in obesity despite higher left ventricular end diastolic pressures. Am Heart J. 2006;152(6):1071-6.
116. Wang TJ, Larson MG, Levy D, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation. 2004;109(5):594-600.
117. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344(18): 1343-50.
118. Verreth W, De Keyzer D, Pelat M, et al. Weight-loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice. Circulation. 2004;110(20):3259-69.
119. Tuck ML, Sowers J, Dornfeld L, Kledzik G, Maxwell M. The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med. 1981;304(16):930-3.
120. Hinderliter A, Sherwood A, Gullette EC, et al. Reduction of left ventricular hypertrophy after exercise and weight loss in overweight patients with mild hypertension. Arch Intern Med. 2002; 162(12): 1333-9.
121. Wirth A, Kroger H. Improvement of left ventricular morphology and function in obese subjects following a diet and exercise program. Int J Obes Relat Metab Disord. 1995;19(1): 61-6.
122. De la Cruz-Munoz N, Messiah SE, Arheart KL, Lopez-Mitnik G, Lipshultz SE, Livingstone A. Bariatric surgery significantly decreases the prevalence of type 2 diabetes mellitus and pre-diabetes among morbidly obese multiethnic adults: long-term results. J Am Coll Surg. 2011;212(4):505-11, Discussion 512-3.
123. Inge TH, Miyano G, Bean J, et al. Reversal of type 2 diabetes mellitus and improvements in cardiovascular risk factors after surgical weight loss in adolescents. Pediatrics. 2009;123(1): 214-22.
124. Bray GA, Ryan DH. Drug treatment of the overweight patient. Gastroenterology. 2007;132(6):2239-52.
125. Leombruni P, Piero A, Lavagnino L, Brustolin A, Campisi S, Fassino S. A randomized, double-blind trial comparing sertraline and fluoxetine 6-month treatment in obese patients with Binge Eating Disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(6):1599-605.
126. Stunkard AJ, Allison KC, Lundgren JD, et al. A paradigm for facilitating pharmacotherapy at a distance: sertraline treatment of the night eating syndrome. J Clin Psychiatry. 2006;67(10): 1568-72.
127. Jordan J, Messerli FH, Lavie CJ, Aepfelbacher FC, Soria F. Reduction of weight and left ventricular mass with serotonin uptake inhibition in obese patients with systemic hypertension. Am J Cardiol. 1995;75(10):743-4.
128. Aronne LJ, Isoldi KK. Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: efficacy. Am J Cardiol. 2007;100(12A):18P-26.
129. Godoy-Matos A, Carraro L, Vieira A, et al. Treatment of obese adolescents with sibutramine: a randomized, double-blind, controlled study. J Clin Endocrinol Metab. 2005;90(3):1460-5.
130. Connolly HM, McGoon MD. Obesity drugs and the heart. Curr Probl Cardiol. 1999;24(12):745-92.
131. Rothman RB, Baumann MH. Appetite suppressants, cardiac valve disease and combination pharmacotherapy. Am J Ther. 2009;16(4):354-64.
132. Dahl CF, Allen MR, Urie PM, Hopkins PN. Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals. BMC Med. 2008;6:34.
133. Bays HE. Lorcaserin: drug profile and illustrative model of the regulatory challenges of weight-loss drug development. Expert Rev Cardiovasc Ther. 2011;9(3):265-77.
134. Hughes TE, Vath JE, Marjason J, Proietto J. ZGN-433 is well-tolerated, reduces body weight rapidly and improves cardiovascular risk markers in obese subjects: The ZAF-001 proof of concept trial. Diabetes. 2011;60(Suppl 66):LB15.
135. Luthin DR. Anti-obesity effects of small molecule melanin-concentrating hormone receptor 1 (MCHR1) antagonists. Life Sci. 2007;81(6):423-40.
136. Rusconi P, Gomez-Marin O, Rossique-Gonzalez M, et al. Carvedilol in children with cardiomyopathy: 3-year experience at a single institution. J Heart Lung Transplant. 2004;23(7): 832-8.
137. Rossner S, Taylor CL, Byington RP, Furberg CD. Long term propranolol treatment and changes in body weight after myocardial infarction. BMJ. 1990;300(6729):902-3.
138. Raji A, Seely EW, Bekins SA, Williams GH, Simonson DC. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care. 2003;26(1): 172-8.